referencesshodhganga.inflibnet.ac.in/bitstream/10603/7195/11/11_references.p… · references 146...
TRANSCRIPT
REFERENCES
References
144
1. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002267/
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
3. Bishop, J. M.; Weinberg, R. A.; How cancer arises Scientific American, I.
Scientific American molecular oncology. Scientific American: 1996.
4. Balmain, A.; Barrett, J. C.; Moses, H.; Renan, M. J. How many mutations are
required for tumorigenesis? Implications from human cancer data. Molecular
carcinogenesis 1993, 7, 139-146.
5. Foulds, L. The experimental study of tumor progression: a review. Cancer
research 1954, 14, 327-339.
6. Kinzler, K. W.; Vogelstein, B. Lessons from Hereditary Review Colorectal
Cancer. Cell 1996, 87, 159-170.
7. Nowell, P. C. The clonal evolution of tumor cell populations. Science 1976,
194, 23-28.
8. Fedi, P., Tronick, S.R. and Aaronson, S.A., Growth factors. In: Cancer
Medicine, Holland, J.F.; Bast, R.C.; Morton, D.L.; Frei, E.; Kufe, D.W.;
Weichselbaum, R.R. (eds), Williams and Wilkins: Baltimore, MD, 1997, pp 41–
64.
9. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell 1995,
81, 323-330.
10. Wyllie, A. H.; Kerr, J. F.; Currie, A. R. Cell death: the significance of apoptosis.
Academic Press: 1980, 68, pp 251-306.
11. Lotem, J.; Sachs, L. Control of apoptosis in hematopoiesis and leukemia by
cytokines, tumor suppressor and oncogenes. Leukemia 1996, 10, 925-31.
12. Evan, G.; Littlewood, T. A matter of life and cell death. Science 1998, 281,
1317-1322.
13. Ishizaki, Y.; Cheng, L.; Mudge, A. W.; Raff, M. C. Programmed cell death by
default in embryonic cells, fibroblasts, and cancer cells. Mol Biol Cell 1995, 6,
1443-58.
14. Giancotti, F. G.; Ruoslahti, E. Integrin signaling. Science 1999, 285, 1028-1033.
15. Green, D. R.; Reed, J. C. Mitochondria and apoptosis. Science 1998, 281, 1309-
12
16. Thornberry, N. A.; Lazebnik, Y. Caspases: enemies within. Science 1998, 281,
1312-1316.
References
145
17. Harris, C. C. p53 Tumor suppressor gene: from the basic research laboratory to
the clinic- an abridged historical perspective. Carcinogenesis 1996, 17, 1187-
1198.
18. Levine, A. J. p53, the cellular gatekeeper review for growth and division. Cell
1997, 88, 323-331.
19. Hayflick, L. Mortality and immortality at the cellular level. A review.
Biochemistry 1997, 62, 1180-1190.
20. Bouck, N.; Stellmach, V.; Hsu, S. C. How tumors become angiogenic. Advances
in cancer research 1996, 69, 135-174.
21. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic
switch during tumorigenesis. Cell 1996, 86, 353-64.
22. Folkman, J. Tumor angiogenesis in Cancer medicine. Williams and Wilkins:
Baltimore, MD, 1997, pp 181–204.
23. Bull, H. A.; Brickell, P. M.; Dowd, P. M. Src-related protein tyrosine kinases
are physically associated with the surface antigen CD36 in human dermal
microvascular endothelial cells. FEBS letters 1994, 351, 41-44.
24. Dameron, K. M.; Volpert, O. V.; Tainsky, M. A.; Bouck, N. Control of
angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science
1994, 265, 1582-1584.
25. Rak, J.; Filmus, J.; Finkenzeller, G.; Grugel, S.; Marme, D.; Kerbel, R. S.
Oncogenes as inducers of tumor angiogenesis. Cancer and Metastasis Reviews
1995, 14, 263-277.
26. Maxwell, P. H.; Wiesener, M. S.; Chang, G. W.; Clifford, S. C.; Vaux, E. C.;
Cockman, M. E.; Wykoff, C. C.; Pugh, C. W.; Maher, E. R.; Ratcliffe, P. J. The
tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-
dependent proteolysis. Nature 1999, 399, 271-275.
27. Sporn, M. B. The war on cancer. Lancet 1996, 347, 1377-81.
28. Loeb, L. A. Mutator phenotype may be required for multistage carcinogenesis.
Cancer Res 1991, 51, 3075-79.
29. Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Genetic instabilities in human
cancers. Nature 1998, 396, 643.
30. Tortora, G. J.; Derrickson, B. Principles of Anatomy and Physiology. John
Wiley & Sons: 2009; pp 959-62.
References
146
31. Cheng, L.; Lai, M. D. Aberrant crypt foci as microscopic precursors of
colorectal cancer. World journal of gastroenterology 2003, 9, 2642.
32. Fenoglio-Preiser, C. M.; Noffsinger, A. Review Article: Aberrant Crypt Foci: A
Review. Toxicologic pathology 1999, 27, 632.
33. Hardy, R. G.; Meltzer, S. J.; Jankowski, J. A. ABC of colorectal cancer.
Molecular basis for risk factors. Brit Med Journal 2000, 321, 886-9.
34. Fearon, E. R.; Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell
1990, 61, 759-767.
35. Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.;
Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M. Identification and
characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66,
589.
36. Powell, S. M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T. M.; Hamilton, S. R.;
Thibodeau, S. N.; Vogelstein, B.; Kinzler, K. W. APC mutations occur early
during colorectal tumorigenesis. Nature 1992, 359, 235-237.
37. Kinzler, K. W.; Nilbert, M. C.; Su, L. K.; Vogelstein, B.; Bryan, T. M.; Levy, D.
B.; Smith, K. J.; Preisinger, A. C.; Hedge, P.; McKechnie, D. Identification of
FAP locus genes from chromosome 5q21. Science 1991, 253, 661-665.
38. Mori, Y.; Nagse, H.; Ando, H.; Horii, A.; Ichii, S.; Nakatsuru, S.; Aoki, T.;
Miki, Y.; Mori, T.; Nakamura, Y. Somatic mutations of the APC gene in
colorectal tumors: mutation cluster region in the APC gene. Human molecular
genetics 1992, 1, 229-233.
39. Solomon, E.; Voss, R.; Hall, V.; Bodmer, W. F.; Jass, J. R.; Jeffreys, A. J.;
Lucibello, F. C.; Patel, I.; Rider, S. H. Chromosome 5 allele loss in human
colorectal carcinomas. 1987, 328, 616-19.
40. Miyaki, M.; Konishi, M.; Kikuchi-Yanoshita, R.; Enomoto, M.; Igari, T.;
Tanaka, K.; Muraoka, M.; Takahashi, H.; Amada, Y.; Fukayama, M.
Characteristics of somatic mutation of the adenomatous polyposis coli gene in
colorectal tumors. Cancer research 1994, 54, 3011-3020.
41. Halling, K. C.; French, A. J.; McDonnell, S. K.; Burgart, L. J.; Schaid, D. J.;
Peterson, B. J.; Moon-Tasson, L.; Mahoney, M. R.; Sargent, D. J.; O'Connell,
M. J. Microsatellite instability and 8p allelic imbalance in stage B2 and C
colorectal cancers. Journal of the National Cancer Institute 1999, 91, 1295-1303.
References
147
42. Konishi, M.; Kikuchi-Yanoshita, R.; Tanaka, K.; Muraoka, M.; Onda, A.;
Okumura, Y.; Kishi, N.; Iwama, T.; Mori, T.; Koike, M. Molecular nature of
colon tumors in hereditary nonpolyposis colon cancer, familial polyposis, and
sporadic colon cancer. Gastroenterology 1996, 111, 307-317.
43. Vogelstein, B.; Fearon, E. R.; Hamilton, S. R.; Kern, S. E.; Preisinger, A. C.;
Leppert, M.; Smits, A. M. M.; Bos, J. L. Genetic alterations during colorectal-
tumor development. New England Journal of Medicine 1988, 319, 525-532.
44. Thibodeau, S. N.; Bren, G.; Schaid, D. Microsatellite instability in cancer of the
proximal colon. Science 1993, 260, 816-9.
45. Kiaris, H.; Spandidos, D. A. Mutations of ras genes in human tumours
(Review). International Journal of Oncology 1995, 7, 413-421.
46. Burt, R. W.; Bishop, D. T.; Lee, R. G.; Albright, L. C.; Skolnick, M. H.
Inheritance of colonic adenomatous polyps and colorectal cancer. Prog Clin Biol
Res 1988, 279, 189- 4.
47. Danes, B. S.; Gardner, E. J.; Lipkin, M. Studies on the identification of genetic
risk for heritable colon cancer. Cancer Detect Prev 1985, 8, 349-65.
48. Doll, R.; Peto, R. The causes of cancer: quantitative estimates of avoidable risks
of cancer in the United States today. J Natl Cancer Inst 1981, 66, 1191-308.
49. Kussin, S. Z.; Lipkin, M.; Winawer, S. J. Inherited colon cancer: clinical
implications. The American journal of gastroenterology 1979, 72, 448-57.
50. Eaden, J. A.; Abrams, K. R.; Mayberry, J. F. The risk of colorectal cancer in
ulcerative colitis: a meta-analysis. Gut 2001, 48, 526.
51. Eaden, J. A.; Mayberry, J. F. Colorectal cancer complicating ulcerative colitis: a
review. The American journal of gastroenterology 2000, 95, 2710-2719.
52. Rustgi, A. K. Hereditary gastrointestinal polyposis and nonpolyposis
syndromes. New England Journal of Medicine 1994, 331, 1694-1702.
53. Houlston, R. S. What we could do now: molecular pathology of colorectal
cancer. Molecular Pathology 2001, 54, 206.
54. De la Chapelle, A. Genetic predisposition to colorectal cancer. Nature Reviews
Cancer 2004, 4, 769-780.
55. Lynch, H. T.; Watson, P.; Lanspa, S. J.; Marcus, J.; Smyrk, T.; Fitzgibbons, R.
J., Jr.; Kriegler, M.; Lynch, J. F. Natural history of colorectal cancer in
References
148
hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). Dis
Colon Rectum 1988, 31, 439-44.
56. Lynch, H. T.; Watson, P.; Kriegler, M.; Lynch, J. F.; Lanspa, S. J.; Marcus, J.;
Smyrk, T.; Fitzgibbons, R. J., Jr.; Cristofaro, G. Differential diagnosis of
hereditary nonpolyposis colorectal cancer (Lynch syndrome I and Lynch
syndrome II). Dis Colon Rectum 1988, 31, 372-7.
57. Lynch, H. T.; Smyrk, T. Hereditary nonpolyposis colorectal cancer (Lynch
syndrome): an updated review. Cancer 1996, 78, 1149-1167.
58. Lynch, H.T.; de la Chapelle, A. Genetic susceptibility to non-polyposis
colorectal cancer. Journal of medical genetics 1999, 36, 801.
59. Lynch, H.T.; de la Chapelle, A. Hereditary colorectal cancer. The New England
journal of medicine 2003, 348, 919.
60. Lynch, H.T.; Lanspa, S.; Smyrk, T.; Boman, B.; Watson, P.; Lynch, J.
Hereditary nonpolyposis colorectal cancer (Lynch syndromes I & II): Genetics,
pathology, natural history, and cancer control, part I. Cancer genetics and
cytogenetics 1991, 53, 143-60.
61. Lynch, H.T.; Smyrk, T.C.; Watson, P.; Lanspa, S.J.; Lynch, J.F. et al. Genetics,
natural history, tumor spectrum, and pathology of hereditary nonpolyposis
colorectal cancer: an updated review. Gastroenterology 1993, 104, 1535.
62. Marra, G.; Boland, C. R. Hereditary nonpolyposis colorectal cancer: the
syndrome, the genes, and historical perspectives. Journal of the National Cancer
Institute 1995, 87, 1114.
63. Groden, J.; Thliveris, A.; Samowitz, W.; Carlson, M.; Gelbert, L.; Albertsen, H.;
Joslyn, G.; Stevens, J.; Spirio, L.; Robertson, M. Identification and
characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66,
589.
64. Kinzler, K. W.; Nilbert, M. C.; Su, L. K.; Vogelstein, B.; Bryan, T. M.; Levy, D.
B.; Smith, K. J.; Preisinger, A. C.; Hedge, P.; McKechnie, D. Identification of
FAP locus genes from chromosome 5q21. Science 1991, 253, 661-665.
65. Fodde, R.; Smits, R.; Clevers, H. APC, signal transduction and genetic
instability in colorectal cancer. Nature Reviews Cancer 2001, 1, 55-67.
66. Itoh, H.; Ohsato, K. Turcot syndrome and its characteristic colonic
manifestations. Diseases of the Colon & Rectum 1985, 28, 399-402.
References
149
67. Foulkes, W. D. A tale of four syndromes: familial adenomatous polyposis,
Gardner syndrome, attenuated APC and Turcot syndrome. QJM 1995, 88, 853-
863.
68. Miyaki, M.; Nishio, J.; Konishi, M.; Kikuchi-Yanoshita, R.; Tanaka, K.;
Muraoka, M.; Nagato, M.; Chong, J. M.; Koike, M.; Terada, T. Drastic genetic
instability of tumors and normal tissues in Turcot syndrome. Oncogene 1997,
15, 2877-2881.
69. Lynch, H. T.; Smyrk, T.; McGinn, T.; Lanspa, S.; Cavalieri, J.; Lynch, J.;
Slominskia Castor, S.; Cayouette, M. C.; Priluck, I.; Luce, M. C. Attenuated
familial adenomatous polyposis (AFAP) a phenotypically and genotypically
distinctive variant of FAP. Cancer 1995, 76, 2427-2433.
70. Knudsen, A. L.; Bisgaard, M. L.; Bulow, S. Attenuated familial adenomatous
polyposis (AFAP): a review of the literature. Familial cancer 2003, 2, 43-55.
71. Hawkins, N. J.; Gorman, P.; Tomlinson, I. P. M.; Bullpitt, P.; Ward, R. L.
Colorectal carcinomas arising in the hyperplastic polyposis syndrome progress
through the chromosomal instability pathway. The American journal of
pathology 2000, 157, 385.
72. Jeevaratnam, P.; Cottier, D. S.; Browett, P. J.; Van De Water, N. S.; Jass, V. P.
J. R. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a
new hereditary bowel cancer syndrome. The Journal of Pathology 1996, 179,
20-25.
73. Deng, G.; Bell, I.; Crawley, S.; Gum, J.; Terdiman, J. P.; Allen, B. A.; Truta, B.;
Sleisenger, M. H.; Kim, Y. S. BRAF mutation is frequently present in sporadic
colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis
colorectal cancer. Clinical cancer research 2004, 10, 191-195.
74. Weisenberger, D. J.; Siegmund, K. D.; Campan, M.; Young, J.; Long, T. I.;
Faasse, M. A.; Kang, G. H.; Widschwendter, M.; Weener, D.; Buchanan, D.
CpG island methylator phenotype underlies sporadic microsatellite instability
and is tightly associated with BRAF mutation in colorectal cancer. Nature
genetics 2006, 38, 787-793.
75. O'Brien, M. J.; Yang, S.; Clebanoff, J. L.; Mulcahy, E.; Farraye, F. A.;
Amorosino, M.; Swan, N. Hyperplastic (serrated) polyps of the colorectum:
relationship of CpG island methylator phenotype and K-ras mutation to location
References
150
and histologic subtype. The American journal of surgical pathology 2004, 28,
423.
76. Westerman, A. M.; Wilson, J. H. P. Peutz-Jeghers syndrome: risks of a
hereditary condition: a clinical review. Scandinavian Journal of
Gastroenterology 1999, 34, 64-70.
77. Boardman, L. A.; Thibodeau, S. N.; Schaid, D. J.; Lindor, N. M.; McDonnell, S.
K.; Burgart, L. J.; Ahlquist, D. A.; Podratz, K. C.; Pittelkow, M.; Hartmann, L.
C. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Annals
of internal medicine 1998, 128, 896.
78. Yoo, L. I.; Chung, D. C.; Yuan, J. LKB1-a master tumour suppressor of the
small intestine and beyond. Nature Reviews Cancer 2002, 2, 529-535.
79. Whittle, D. O.; Lee, M. G.; Hanchard, B. Juvenile polyposis syndrome. West
Indian Medical Journal 2010, 59, 306.
80. Houlston, R.; Bevan, S.; Williams, A.; Young, J.; Dunlop, M.; Rozen, P.; Eng,
C.; Markie, D.; Woodford-Richens, K.; Rodriguez-Bigas, M. A. Mutations in
DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a
minority of cases. Human molecular genetics 1998, 7, 1907-1912.
81. Liaw, D.; Marsh, D. J.; Li, J.; Dahia, P. L. M.; Wang, S. I.; Zheng, Z.; Bose, S.;
Call, K. M.; Tsou, H. C.; Peacoke, M. Germline mutations of the PTEN gene in
Cowden disease, an inherited breast and thyroid cancer syndrome. Nature
genetics 1997, 16, 64-67.
82. Gretzula, J. C.; Hevia, O.; Shachner, L. S.; DiLiberti, J. H.; Ruvalcaba, R. H. A.;
Schimshock, J. R.; Weleber, R. G.; Halal, F.; Lipson, M. H.; Blumberg, B.
Ruvalcaba-Myhre-Smith Syndrome. Pediatric dermatology 1988, 5, 28-32.
83. de Leon, M. P.; Roncucci, L.; Di Donato, P.; Tassi, L.; Smerieri, O.; Amorico,
M. G.; Malagoli, G.; De Maria, D.; Antonioli, A.; Chahin, N. J. Pattern of
epithelial cell proliferation in colorectal mucosa of normal subjects and of
patients with adenomatous polyps or cancer of the large bowel. Cancer research
1988, 48, 4121-26.
84. Ponz de Leon, M.; Di Gregorio, C. Pathology of colorectal cancer. Digestive
and Liver Disease 2001, 33, 372-388.
85. Austoker, J. Screening for colorectal cancer. Brit Med Journal 1994, 309, 382-6.
References
151
86. O'Brien, M. J.; Winawer, S. J.; Zauber, A. G.; Gottlieb, L. S.; Sternberg, S. S.;
Diaz, B.; Dickersin, G. R.; Ewing, S.; Geller, S.; Kasimian, D. The National
Polyp Study. Patient and polyp characteristics associated with high-grade
dysplasia in colorectal adenomas. Gastroenterology 1990, 98, 371-9.
87. O'Connell, J. B.; Maggard, M. A.; Ko, C. Y. Colon cancer survival rates with
the new American Joint Committee on Cancer sixth edition staging. Journal of
the National Cancer Institute 2004, 96, 1420-1425.
88. Sobin, L. H. TNM classification of malignant tumours. Wiley-Blackwell: 2009.
89. Compton, C. C.; Greene, F. L. The staging of colorectal cancer: 2004 and
beyond. CA: A Cancer Journal for Clinicians 2004, 54, 295-308.
90. Majumdar, S. R.; Fletcher, R. H.; Evans, A. T. How does colorectal cancer
present and quest; symptoms, duration, and clues to location. The American
journal of gastroenterology 1999, 94, 3039-3045.
91. Johnson, I. T.; Lund, E. K. Review article: nutrition, obesity and colorectal
cancer. Alimentary Pharmacology & Therapeutics 2007, 26, 161-181.
92. Larsson, S. C.; Wolk, A. Meat consumption and risk of colorectal cancer: a
meta-analysis of prospective studies. International Journal of Cancer 2006, 119,
2657-2664.
93. Lipkin, M.; Reddy, B.; Newmark, H.; Lamprecht, S. A. Dietary factors in
human colorectal cancer. Annual review of nutrition 1999, 19, 545-586.
94. Norat, T.; Riboli, E. Dairy products and colorectal cancer. A review of possible
mechanisms and epidemiological evidence. European journal of clinical
nutrition 2003, 57, 1-17.
95. Martínez, M. E.; Willett, W. C. Calcium, vitamin D, and colorectal cancer: a
review of the epidemiologic evidence. Cancer Epidemiology Biomarkers &
Prevention 1998, 7, 163.
96. DuBois, R. N.; Giardiello, F. M.; Smalley, W. E. Nonsteroidal anti-
inflammatory drugs, eicosanoids, and colorectal cancer prevention.
Gastroenterology Clinics of North America 1996, 25, 773.
97. Dubé, C.; Rostom, A.; Lewin, G.; Tsertsvadze, A.; Barrowman, N.; Code, C.;
Sampson, M.; Moher, D. The use of aspirin for primary prevention of colorectal
cancer: a systematic review prepared for the US Preventive Services Task Force.
Annals of internal medicine 2007, 146, 365.
References
152
98. Grodstein, F.; Newcomb, P. A.; Stampfer, M. J. Postmenopausal hormone
therapy and the risk of colorectal cancer: a review and meta-analysis. The
American journal of medicine 1999, 106, 574-582.
99. Munkholm, P. Review article: the incidence and prevalence of colorectal cancer
in inflammatory bowel disease. Alimentary pharmacology and therapeutics
2003, 18, 1-5.
100. Larsson, S. C.; Orsini, N.; Wolk, A. Diabetes mellitus and risk of colorectal
cancer: a meta-analysis. Journal of the National Cancer Institute 2005, 97, 1679-
1687.
101. England, W. L.; Halls, J. J.; Hunt, V. B. Strategies for screening for colorectal
carcinoma. Medical Decision Making 1989, 9, 3-13.
102. Winawer, S. J.; Prorok, P.; Macrae, F.; Bralow, S. P. Surveillance and early
diagnosis of colorectal cancer. Cancer detection and prevention 1985, 8, 373-92.
103. Unger, S. W.; Wanebo, H. J. Colonoscopy: an essential monitoring technique
after resection of colorectal cancer. The American Journal of Surgery 1983, 145,
71-76.
104. Toribara, N. W.; Sleisenger, M. H. Screening for colorectal cancer. New
England Journal of Medicine 1995, 332, 861-867.
105. Fuchs, C. S.; Giovannucci, E. L.; Colditz, G. A.; Hunter, D. J.; Speizer, F. E.;
Willett, W. C. A prospective study of family history and the risk of colorectal
cancer. New England Journal of Medicine 1994, 331, 1669-1674.
106. Petersen, G. M.; Boyd, P. A. Gene tests and counseling for colorectal cancer
risk: lessons from familial polyposis. Journal of the National Cancer Institute.
Monographs 1995, 67-71.
107. Bruckner, H. W.; Merrick, J. P. M. Adenocarcinoma of the colon and rectum.
Cancer Medicine 5th edition. Available from URL: http://www. ncbi. nlm. nih.
gov/bookshelf/br. fcgi 2000, 1472-1520.
108. Johnson, M. G.; Jolly, P. C. Analysis of a mass colorectal cancer screening
program for cost-effectiveness. The American Journal of Surgery 1987, 154,
261-263.
109. McGarrity, T. J.; Long, P. A.; Peiffer, L. P. Results of a repeat television-
advertised mass screening program for colorectal cancer using fecal occult
blood tests. The American journal of gastroenterology 1990, 85, 266-70.
References
153
110. Walsh, J. M. E.; Terdiman, J. P. Colorectal cancer screening: scientific review.
JAMA, the journal of the American Medical Association 2003, 289, 1288-1296.
111. http://www.emedicinehealth.com/sigmoidoscopy/article_em.htm
112. http://en.wikipedia.org/wiki/Colonoscopy
113. Hundt, S.; Haug, U.; Brenner, H. Blood markers for early detection of colorectal
cancer: a systematic review. Cancer Epidemiology Biomarkers & Prevention
2007, 16, 1935-53.
114. McLeod, H. L.; Murray, G. I. Tumour markers of prognosis in colorectal cancer.
British journal of cancer 1999, 79, 191-203.
115. Gold, P.; Freedman, S. O. Specific carcinoembryonic antigens of the human
digestive system. The Journal of experimental medicine 1965, 122, 467-81.
116. Gold, P.; Shuster, J.; Freedman, S. O. Carcinoembryonic antigen (CEA) in
clinical medicine. Historical perspectives, pitfalls and projections. Cancer 1978,
42, 1399-1405.
117. Bates, S. E.; Longo, D. L. Use of serum tumor markers in cancer diagnosis and
management, Semin Oncol ,1987, 14(2), 102-38.
118. Mayer, R. J.; Garnick, M. B.; Steele Jr, G. D.; Zamcheck, N. Carcinoembryonic
antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer.
Cancer 1978, 42, 1428-1433.
119. Steele Jr, G.; Zamcheck, N. The use of carcinoembryonic antigen in the clinical
management of patients with colorectal cancer. Cancer detection and prevention
1985, 8, 421-7.
120. Koprowski, H.; Herlyn, M.; Steplewski, Z.; Sears, H. F. Specific antigen in
serum of patients with colon carcinoma. Science 1981, 212, 53-55.
121. Campo, E.; Munoz, J.; Miquel, R.; PalacAn, A.; Cardesa, A.; Sloane, B. F.;
Emmert-Buck, M. R. Cathepsin B expression in colorectal carcinomas correlates
with tumor progression and shortened patient survival. The American journal of
pathology 1994, 145, 301-309.
122. Jessup, J. M. Cathepsin B and other proteases in human colorectal carcinoma.
The American journal of pathology 1994, 145, 253-62.
123. Notani, P. N. Global variation in cancer incidence and mortality. Curr Sci 2001,
81, 465-74.
References
154
124. Center, M. M.; Jemal, A.; Smith, R. A.; Ward, E. Worldwide variations in
colorectal cancer. CA: a cancer journal for clinicians 2009, 59, 366.
125. Center, M. M.; Jemal, A.; Ward, E. International trends in colorectal cancer
incidence rates. Cancer Epidemiology Biomarkers & Prevention 2009, 18, 1688.
126. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Estimating the world cancer
burden: Globocan 2000. International Journal of Cancer 2001, 94, 153-156.
127. Parkin, D. M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA:
a cancer journal for clinicians 2005, 55, 74.
128. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M.; Boyle, P.
Estimates of the cancer incidence and mortality in Europe in 2006. Annals of
Oncology 2007, 18, 581.
129. Parkin, D. M.; Pisani, P.; Ferlay, J. Estimates of the worldwide incidence of 25
major cancers in 1990. International Journal of Cancer 1999, 80, 827-841.
130. Parkin, D. M.; Whelan, S. L.; Ferlay, J.; Storm, H. H. Cancer incidence in five
continents. Intl Agency for Research on Cancer: 2006.
131. Sung, J. J. Y.; Lau, J. Y. W.; Goh, K. L.; Leung, W. K. Increasing incidence of
colorectal cancer in Asia: implications for screening. The Lancet Oncology
2005, 6, 871-876.
132. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011. CA: A
Cancer Journal for Clinicians 61, 212-236.
133. Jemal, A.; Bray, F.; Center, M. M.; Ferlay, J.; Ward, E.; Forman, D. Global
cancer statistics. CA: A Cancer Journal for Clinicians 61, 69-90.
134. Rastogi, T.; Devesa, S.; Mangtani, P.; Mathew, A.; Cooper, N.; Kao, R.; Sinha,
R. Cancer incidence rates among South Asians in four geographic regions:
India, Singapore, UK and US. International journal of epidemiology 2008, 37,
147-160.
135. de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.;
Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G. Leucovorin and
fluorouracil with or without oxaliplatin as first-line treatment in advanced
colorectal cancer. Journal of Clinical Oncology 2000, 18, 2938.
136. Janne, P. A.; Mayer, R. J. Chemoprevention of colorectal cancer. New England
Journal of Medicine 2000, 342, 1960.
References
155
137. Gupta, R. A.; DuBois, R. N. Colorectal cancer prevention and treatment by
inhibition of cyclooxygenase-2. Nature Reviews Cancer 2001, 1, 11-21.
138. Dubois, R. N.; Giardiello, F. M.; Smalley, W. E. Nonsteroidal anti-inflammatory
drugs, eicosanoids, and colorectal cancer prevention. Gastroenterology Clinics
of North America 1996, 25, 773.
139. Dubois, R. N. Review article: cyclooxygenase–a target for colon cancer
prevention. Alimentary Pharmacology & Therapeutics 2000, 14, 64-67.
140. Kopp, E.; Ghosh, S. Inhibition of NF-kappa B by sodium salicylate and aspirin.
Science 1994, 265, 956-959.
141. Mackenzie, G. G.; Rasheed, S.; Wertheim, W.; Rigas, B. NO-donating NSAIDs,
PPAR δ, and cancer: does PPAR δ contribute to colon carcinogenesis? PPAR
research 2008, 1-11.
142. Kim, Y. I. Folate and colorectal cancer: An evidence based critical review.
Molecular nutrition & food research 2007, 51, 267-292.
143. Kim, Y. I. Folate and DNA methylation: a mechanistic link between folate
deficiency and colorectal cancer? Cancer Epidemiology Biomarkers &
Prevention 2004, 13, 511.
144. Martínez, M. E.; Willett, W. C. Calcium, vitamin D, and colorectal cancer: a
review of the epidemiologic evidence. Cancer Epidemiology Biomarkers &
Prevention 1998, 7, 163.
145. Grodstein, F.; Newcomb, P. A.; Stampfer, M. J. Postmenopausal hormone
therapy and the risk of colorectal cancer: a review and meta-analysis. The
American journal of medicine 1999, 106, 574-582.
146. Simmonds, P. C. Palliative chemotherapy for advanced colorectal cancer:
systematic review and meta-analysis. Colorectal Cancer Collaborative Group.
Brit Med Journal (Clinical research ed.) 2000, 321, 531.
147. Carethers, J. M. Review: Systemic treatment of advanced colorectal cancer:
Tailoring therapy to the tumor. Therapeutic Advances in Gastroenterology 2008,
1, 33.
148. Kelly, H.; Goldberg, R. M. Systemic therapy for metastatic colorectal cancer:
current options, current evidence. Journal of Clinical Oncology 2005, 23, 4553.
149. Machover, D. A comprehensive review of 5-fluorouracil and leucovorin in
patients with metastatic colorectal carcinoma. Cancer 1997, 80, 1179-1187.
References
156
150. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.;
Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E. Bevacizumab plus
irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New
England Journal of Medicine 2004, 350, 2335.
151. Chung, K. Y.; Shia, J.; Kemeny, N. E.; Shah, M.; Schwartz, G. K.; Tse, A.;
Hamilton, A.; Pan, D.; Schrag, D.; Schwartz, L. Cetuximab shows activity in
colorectal cancer patients with tumors that do not express the epidermal growth
factor receptor by immunohistochemistry. Journal of Clinical Oncology 2005,
23, 1803.
152. http://www.uptodate.com/contents/patient-information-colorectal-cancer-
treatment-metastatic-cancer-beyond-the-basics
153. Sloan, J. A.; Goldberg, R. M.; Sargent, D. J.; Vargas-Chanes, D.; Nair, S.; Cha,
S. S.; Novotny, P. J.; Poon, M. A.; O’Connell, M. J.; Loprinzi, C. L. Women
experience greater toxicity with fluorouracil-based chemotherapy for colorectal
cancer. Journal of Clinical Oncology 2002, 20, 1491.
154. Renehan, A. G.; Egger, M.; Saunders, M. P.; O'Dwyer, S. T. Impact on survival
of intensive follow up after curative resection for colorectal cancer: systematic
review and meta-analysis of randomised trials. Brit Med Journal 2002, 324, 813.
155. Farnsworth, N. R.; Soejarto, D. D. Global importance of medicinal plants. The
conservation of medicinal plants: proceedings of an International consultation,
21-27 March 1988 held at Chiang Mai, Thailand 1991, 25.
156. Fayed, S. A. Antioxidant and anticancer activities of Citrus reticulate (Petitgrain
Mandarin) and Pelargonium graveolens (Geranium) essential oils. Research
Journal of Agriculture and Biological Sciences 2009, 5, 740-747.
157. Modzelewska, A.; Sur, S.; Kumar, S. K.; Khan, S. R. Sesquiterpenes: natural
products that decrease cancer growth. Current Medicinal Chemistry-Anti-
Cancer Agents 2005, 5, 477-499.
158. Rao, A. V.; Sung, M. K. Saponins as anticarcinogens. Journal of Nutrition 1995,
125, 717S.
159. Arroo, R. R. J.; Alfermann, A. W.; Medarde, M.; Petersen, M.; Pras, N.;
Woolley, J. G. Plant cell factories as a source for anti-cancer lignans.
Phytochemistry Reviews 2002, 1, 27-35.
References
157
160. Dembitsky, V. M. Chemistry and biodiversity of the biologically active natural
glycosides. Chemistry and biodiversity 2004, 1, 673-781.
161. Siripong, P.; Yahuafai, J.; Shimizu, K.; Ichikawa, K.; Yonezawa, S.; Asai, T.;
Kanokmedakul, K.; Ruchirawat, S.; Oku, N. Induction of apoptosis in tumor
cells by three naphthoquinone esters isolated from Thai medicinal plant:
Rhinacanthus nasutus KURZ. Biological and pharmaceutical bulletin 2006, 29,
2070-2076.
162. Shukla, Y.; Singh, M. Cancer preventive properties of ginger: a brief review.
Food and chemical toxicology 2007, 45, 683-690.
163. Maheshwari, R. K.; Singh, A. K.; Gaddipati, J.; Srimal, R. C. Multiple
biological activities of curcumin: a short review. Life sciences 2006, 78, 2081.
164. Lee, S. K.; Nam, K. A.; Heo, Y. H. Cytotoxic activity and G2/M cell cycle
arrest mediated by antofine, a phenanthroindolizidine alkaloid isolated from
Cynanchum paniculatum. Planta medica 2003, 69, 21-25.
165. Chen, A.; Xu, J.; Johnson, A. C. Curcumin inhibits human colon cancer cell
growth by suppressing gene expression of epidermal growth factor receptor
through reducing the activity of the transcription factor Egr-1. Oncogene 2005,
25, 278-287.
166. Schwartsmann, G.; Ratain, M. J.; Cragg, G. M.; Wong, J. E.; Saijo, N.;
Parkinson, D. R.; Fujiwara, Y.; Pazdur, R.; Newman, D. J.; Dagher, R.
Anticancer drug discovery and development throughout the world. Journal of
clinical oncology 2002, 20, 47.
167. Fouche, G.; Cragg, G. M.; Pillay, P.; Kolesnikova, N.; Maharaj, V. J.; Senabe, J.
In vitro anticancer screening of South African plants. Journal of
ethnopharmacology 2008, 119, 455-461.
168. Mothana, R. A.; Lindequist, U.; Gruenert, R.; Bednarski, P. J. Studies of the in
vitro anticancer, antimicrobial and antioxidant potentials of selected Yemeni
medicinal plants from the island Soqotra. BMC Complementary and Alternative
Medicine 2009, 9, 7.
169. Murakami, A.; Jiwajinda, S.; Koshimizu, K.; Ohigashi, H. Screening for in vitro
anti-tumor promoting activities of edible plants from Thailand. Cancer letters
1995, 95, 139-146.
References
158
170. Rastogi, R. P.; Dhawan, B. N. Anticancer and antiviral activities in Indian
medicinal plants: a review. Drug development research 1990, 19, 1-12.
171. Efferth, T.; Li, P. C. H.; Konkimalla, V. S. B.; Kaina, B. From traditional
Chinese medicine to rational cancer therapy. Trends in Molecular Medicine
2007, 13, 353-361.
172. de Mesquita, M. L.; de Paula, J. E.; Pessoa, C.; de Moraes, M. O.; Costa-Lotufo,
L. V.; Grougnet, R.; Michel, S.; Tillequin, F.; Espindola, L. S. Cytotoxic activity
of Brazilian Cerrado plants used in traditional medicine against cancer cell lines.
Journal of Ethnopharmacol 2009, 123, 439-45.
173. Valeriote, F.; Grieshaber, C. K. Discovery and development of anticancer agents
from plants. Journal of Experimental Therapeutics and Oncology 2002, 2, 228-
236.
174. Ernst, M. D. Harmless herbs? A review of the recent literature. The American
journal of medicine 1998, 104, 170-178.
175. Taraphdar, A. K.; Roy, M.; Bhattacharya, R. K. Natural products as inducers of
apoptosis: Implication for cancer therapy and prevention. Curr Sci 2001, 80,
1387-96.
176. Balunas, M. J.; Kinghorn, A. D. Drug discovery from medicinal plants. Life Sci
2005, 78, 431-41.
177. Cragg, G. M.; Newman, D. J. Discovery and development of antineoplastic
agents from natural sources. Cancer investigation 1999, 17, 153-163.
178. Cragg, G. M.; Newman, D. J. Antineoplastic agents from natural sources:
achievements and future directions. Expert Opinion on Investigational Drugs
2000, 9, 2783-2797.
179. Cragg, G. M.; Newman, D. J. Plants as a source of anti-cancer agents. Journal of
Ethnopharmacol 2005, 100, 72-79.
180. da Rocha, A. B.; Lopes, R. M.; Schwartsmann, G. Natural products in
anticancer therapy. Current Opinion in pharmacology 2001, 1, 364-369.
181. Gordaliza, M. Natural products as leads to anticancer drugs. Clinical and
Translational Oncology 2007, 9, 767-776.
182. Grothaus, G.; Cragg, M.; Newman, J. Plant Natural Products in Anticancer Drug
Discovery. In Current Organic Chemistry, Bentham Science Publishers, 2010,
14, pp 1781-1791.
References
159
183. Lamari, F. N.; Cordopatis, P. Exploring the Potential of Natural Products in
Cancer Treatment Anticancer therapeutics 2008, 1-16.
184. Nobili, S.; Lippi, D.; Witort, E.; Donnini, M.; Bausi, L.; Mini, E.; Capaccioli, S.
Natural compounds for cancer treatment and prevention. Pharmacological
research 2009, 59, 365-378.
185. Wang, H. K. Plant-derived anticancer agents currently in clinical use or in
clinical trials. I Drugs: the investigational drugs journal 1998, 1, 92.
186. Suffness, M.; Newman, D. J.; Snader, K. Discovery and development of
antineoplastic agents from natural sources. Bioorganic Marine Chemistry 1989,
3, 131-168.
187. Wall, M. E. Camptothecin and taxol: discovery to clinic. Medicinal research
reviews 1998, 18, 299-314.
188. Joensuu, H.; Kellokumpu-Lehtinen, P. L.; Bono, P.; Alanko, T.; Kataja, V.;
Asola, R.; Utriainen, T.; Kokko, R.; Hemminki, A.; Tarkkanen, M. Adjuvant
docetaxel or vinorelbine with or without trastuzumab for breast cancer. New
England Journal of Medicine 2006, 354, 809-820.
189. Saloustros, E.; Georgoulias, V. Docetaxel in the treatment of advanced non-
small-cell lung cancer. Expert review of anticancer therapy 2008, 8, 1207-1222.
190. Ray-Coquard, I. Docetaxel and ovarian cancer. Bulletin du cancer 2004, 91,
159-65.
191. Clark, P. I.; Slevin, M. L. The clinical pharmacology of etoposide and
teniposide. Clinical pharmacokinetics 1987, 12, 223-52.
192. Hande, K. R. Etoposide: four decades of development of a topoisomerase II
inhibitor. European Journal of Cancer 1998, 34, 1514-1521.
193. Houghton, P. J.; Cheshire, P. J.; Hallman, J. D.; Lutz, L.; Friedman, H. S.;
Danks, M. K.; Houghton, J. A. Efficacy of topoisomerase I inhibitors, topotecan
and irinotecan, administered at low dose levels in protracted schedules to mice
bearing xenografts of human tumors. Cancer chemotherapy and pharmacology
1995, 36, 393-403.
194. Blagosklonny, M. V.; Fojo, T. Molecular effects of paclitaxel: myths and reality
(a critical review). International journal of cancer 1999, 83, 151-156.
195. Jordan, M. A.; Thrower, D.; Wilson, L. Mechanism of inhibition of cell
proliferation by Vinca alkaloids. Cancer research 1991, 51, 2212-22.
References
160
196. Van Tellingen, O.; Sips, J. H.; Beijnen, J. H.; Bult, A.; Nooijen, W. J.
Pharmacology, bio-analysis and pharmacokinetics of the vinca alkaloids and
semi-synthetic derivatives (review). Anticancer research 1992, 12, 1699-1715.
197. HemaIswarya, S.; Doble, M. Potential synergism of natural products in the
treatment of cancer. Phytotherapy research 2006, 20, 239-249.
198. Singh, S.; Aggarwal, B. B. Activation of transcription factor NF-kappa B is
suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995,
270, 2, 4995-5000.
199. Singh, S.; Natarajan, K.; Aggarwal, B. B. Capsaicin (8-methyl-N-vanillyl-6-
nonenamide) is a potent inhibitor of nuclear transcription factor-kappa B
activation by diverse agents. The Journal of Immunology 1996, 157, 4412-4420.
200. Estrov, Z.; Shishodia, S.; Faderl, S.; Harris, D.; Van, Q.; Kantarjian, H. M.;
Talpaz, M.; Aggarwal, B. B. Resveratrol blocks interleukin-1β induced
activation of the nuclear transcription factor NF-κB, inhibits proliferation,
causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells.
Blood 2003, 102, 987-995.
201. Kumar, A.; Dhawan, S.; Aggarwal, B. B. Emodin (3-methyl-1,6,8-
trihydroxyanthraquinone) inhibits TNF-induced NF-kappaB activation, I kappa
B degradation, and expression of cell surface adhesion proteins in human
vascular endothelial cells. Oncogene 1998, 17, 913-8.
202. Chaturvedi, M. M.; Kumar, A.; Darnay, B. G.; Chainy, G. B. N.; Agarwal, S.;
Aggarwal, B. B. Sanguinarine (pseudochelerythrine) is a potent inhibitor of NF-
κB activation, NF-κB phosphorylation, and degradation. Journal of Biological
Chemistry 1997, 272, 30129-34.
203. Takada, Y.; Aggarwal, B. B. Flavopiridol Inhibits NF-κB Activation Induced by
Various Carcinogens and Inflammatory Agents through Inhibition of Iκ-B
αKinase and p65 Phosphorylation. Journal of Biological Chemistry 2004, 279,
4750-59.
204. Dorai, T.; Aggarwal, B. B. Role of chemopreventive agents in cancer therapy.
Cancer letters 2004, 215, 129-140.
205. Korutla, L.; Cheung, J. Y.; Mendelsohn, J.; Kumar, R. Inhibition of ligand-
induced activation of epidermal growth factor receptor tyrosine phosphorylation
by curcumin. Carcinogenesis 1995, 16, 1741-5.
References
161
206. Sachinidis, A.; Seul, C.; Seewald, S.; Ahn, H.; Ko, Y.; Vetter, H. Green tea
compounds inhibit tyrosine phosphorylation of PDGF beta-receptor and
transformation of A172 human glioblastoma. FEBS Lett 2000, 471, 51-5.
207. Anuchapreeda, S.; Leechanachai, P.; Smith, M. M.; Ambudkar, S. V.;
Limtrakul, P. N. Modulation of P-glycoprotein expression and function by
curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 2002, 64,
573-82.
208. Hong, J.; Lambert, J. D.; Lee, S. H.; Sinko, P. J.; Yang, C. S. Involvement of
multidrug resistance-associated proteins in regulating cellular levels of (-)-
epigallocatechin-3-gallate and its methyl metabolites. Biochem Biophys Res
Commun 2003, 310, 222-7.
209. Mukhopadhyay, A.; Banerjee, S.; Stafford, L. J.; Xia, C.; Liu, M.; Aggarwal, B.
B. Curcumin-induced suppression of cell proliferation correlates with down-
regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein
phosphorylation. Oncogene 2002, 21, 8852-61.
210. Gupta, S.; Hussain, T.; Mukhtar, H. Molecular pathway for (-)-epigallocatechin-
3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma
cells. Arch Biochem Biophys 2003, 410, 177-85.
211. Dong, Z. Molecular mechanism of the chemopreventive effect of resveratrol.
Mutat Res 2003, 523/524, 145-50.
212. Plummer, S. M.; Holloway, K. A.; Manson, M. M.; Munks, R. J.; Kaptein, A.;
Farrow, S.; Howells, L. Inhibition of cyclo-oxygenase 2 expression in colon
cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB
activation via the NIK/IKK signalling complex. Oncogene 1999, 18, 6013-20.
213. Wang, I. K.; Lin-Shiau, S. Y.; Lin, J. K. Induction of apoptosis by apigenin and
related flavonoids through cytochrome c release and activation of caspase-9 and
caspase-3 in leukaemia HL-60 cells. Eur J Cancer 1999, 35, 1517-25.
214. Adhami, V. M.; Siddiqui, I. A.; Ahmad, N.; Gupta, S.; Mukhtar, H. Oral
consumption of green tea polyphenols inhibits insulin-like growth factor-I-
induced signaling in an autochthonous mouse model of prostate cancer. Cancer
Res 2004, 64, 8715-22.
215. Reddy, S.; Aggarwal, B. B. Curcumin is a non-competitive and selective
inhibitor of phosphorylase kinase. FEBS Lett 1994, 341, 19-22.
References
162
216. Leu, T. H.; Su, S. L.; Chuang, Y. C.; Maa, M. C. Direct inhibitory effect of
curcumin on Src and focal adhesion kinase activity. Biochem Pharmacol 2003,
66, 2323-31.
217. D'Autréaux, B.; Toledano, M. B. ROS as signalling molecules: mechanisms that
generate specificity in ROS homeostasis. Nature Reviews Molecular Cell
Biology 2007, 8, 813-824.
218. Jin, Z. G.; Berk, B. C. SOXF: redox mediators of vascular smooth muscle cell
growth. Heart 2004, 90, 488-90.
219. Bandyopadhyay U, Das D, Banerjee R. K. Reactive oxygen species: Oxidative
damage and pathogenesis. Curr Sci 1999, 77, 658-66.
220. Fruehauf, J. P.; Meyskens, F. L. Reactive oxygen species: a breath of life or
death? Clinical Cancer Research 2007, 13, 789-94.
221. Valko, M.; Rhodes, C. J.; Moncol, J.; Izakovic, M.; Mazur, M. Free radicals,
metals and antioxidants in oxidative stress-induced cancer. Chemico-biological
interactions 2006, 160, 1-40.
222. Singh, K. K. Mitochondria damage checkpoint, aging, and cancer. Annals of the
New York Academy of Sciences 2006, 1067, 182-190.
223. Apel, K.; Hirt, H. Reactive oxygen species: metabolism, oxidative stress, and
signal transduction. Annu. Rev. Plant Biol. 2004, 55, 373-399.
224. Armstrong, J. S. Mitochondrial membrane permeabilization: the sine qua non
for cell death. Bioessays 2006, 28, 253-260.
225. Newmeyer, D. D.; Ferguson-Miller, S. Mitochondria: Releasing Power for Life
and Unleashing the Machineries of Death. Cell 2003, 112, 481-490.
226. Chipuk, J. E.; Bouchier-Hayes, L.; Green, D. R. Mitochondrial outer membrane
permeabilization during apoptosis: the innocent bystander scenario. Cell Death
and Differentiation 2006, 13, 1396-1402.
227. Spierings, D.; McStay, G.; Saleh, M.; Bender, C.; Chipuk, J.; Maurer, U.; Green,
D. R. Connected to death: the (unexpurgated) mitochondrial pathway of
apoptosis. Science's STKE 2005, 310, 66-67.
228. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points. Cell 2004,
116, 205-219.
References
163
229. Chipuk, J. E.; Green, D. R. Do inducers of apoptosis trigger caspase-
independent cell death? Nature Reviews Molecular Cell Biology 2005, 6, 268-
275.
230. Ricci, J. E.; Waterhouse, N.; Green, D. R. Mitochondrial functions during cell
death, a complex (I-V) dilemma. Cell Death and Differentiation 2003, 10, 488-
492.
231. Ludovico, P.; Sansonetty, F.; Carte-Real, M. Assessment of mitochondrial
membrane potential in yeast cell populations by flow cytometry. Microbiology
2001, 147, 3335-43.
232. Gottlieb, E.; Vander Heiden, M. G.; Thompson, C. B. Bcl-xL prevents the initial
decrease in mitochondrial membrane potential and subsequent reactive oxygen
species production during tumor necrosis factor alpha-induced apoptosis.
Molecular and Cellular Biology 2000, 20, 5680-89.
233. Gottlieb, E.; Armour, S. M.; Harris, M. H.; Thompson, C. B. Mitochondrial
membrane potential regulates matrix configuration and cytochrome c release
during apoptosis. Cell Death and Differentiation 2003, 10, 709-717.
234. Dey, R.; Moraes, C. T. Lack of oxidative phosphorylation and low
mitochondrial membrane potential decrease susceptibility to apoptosis and do
not modulate the protective effect of Bcl-xL in osteosarcoma cells. Journal of
Biological Chemistry 2000, 275, 7087-94.
235. Johnson, D. G.; Walker, C. L. Cyclins and cell cycle checkpoints. Annu Rev
Pharmacol Toxicol 1999, 39, 295-312.
236. Pietenpol, J. A.; Stewart, Z. A. Cell cycle checkpoint signaling: cell cycle arrest
versus apoptosis. Toxicology 2002, 181-182, 475-81.
237. Aas, T.; Borresen, A. L.; Geisler, S.; Smith-Sorensen, B.; Johnsen, H.; Varhaug,
J. E.; Akslen, L. A.; Lonning, P. E. Specific p53 mutations are associated with
de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996, 2,
811-4.
238. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-dependent apoptosis
modulates the cytotoxicity of anticancer agents. Cell 1993, 74, 957-67.
239. Roberts, J. J.; Thomson, A. J. The mechanism of action of antitumor platinum
compounds. Prog Nucleic Acid Res Mol Biol 1979, 22, 71-133.
References
164
240. Paules, R. S.; Levedakou, E. N.; Wilson, S. J.; Innes, C. L.; Rhodes, N.; Tlsty,
T. D.; Galloway, D. A.; Donehower, L. A.; Tainsky, M. A.; Kaufmann, W. K.
Defective G2 checkpoint function in cells from individuals with familial cancer
syndromes. Cancer Res 1995, 55, 1763-73.
241. Agarwal, M. L.; Agarwal, A.; Taylor, W. R.; Stark, G. R. p53 controls both the
G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest
in human fibroblasts. Proc Natl Acad Sci U S A 1995, 92, 8493-7.
242. Gorbsky, G. J. Cell cycle checkpoints: arresting progress in mitosis. Bioessays
1997, 19, 193-7.
243. Schiff, P. B.; Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast
cells. Proc Natl Acad Sci U S A 1980, 77, 1561-5.
244. Di Leonardo, A.; Khan, S. H.; Linke, S. P.; Greco, V.; Seidita, G.; Wahl, G. M.
DNA rereplication in the presence of mitotic spindle inhibitors in human and
mouse fibroblasts lacking either p53 or pRb function. Cancer Res 1997, 57,
1013-9.
245. Khan, S. H.; Wahl, G. M. p53 and pRb prevent rereplication in response to
microtubule inhibitors by mediating a reversible G1 arrest. Cancer Res 1998, 58,
396-401.
246. Woods, C. M.; Zhu, J.; McQueney, P. A.; Bollag, D.; Lazarides, E. Taxol-
induced mitotic block triggers rapid onset of a p53-independent apoptotic
pathway. Mol Med 1995, 1, 506-26.
247. http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/D
efault.aspx?ATCCNum=HTB-38&Template=cellBiology
248. http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/D
efault.aspx?ATCCNum=CCL-222&Template=cellBiology
249. http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/D
efault.aspx?ATCCNum=CCL-6&Template=cellBiology
250. Bharati, A. C.; Sahu, A. N. Ethnobotany, phytochemistry and pharmacology of
Biophytum sensitivum DC. Pharmacognosy Reviews 2012, 6, 68-73.
251. Natarajan, D.; Shivakumar, M. S.; Srinivasan, R. Antibacterial activity of leaf
extracts of Biophytum sensitivum (L.) DC. J. Pharm. Sci. and Res. 2010, 2, 717-
720.
References
165
252. Mali, P. Y.; Bhadane, V. V. Some rare plants of ethnomedicinal properties from
Jalgaon district of Maharashtra. International Journal of Green Pharmacy 2008,
2, 76-78.
253. Binny, K.; Kumar, S.; Thomas, D. Anti-inflammatory and antipyretic properties
of the rhizome of costus speciosus (koen.) SM. Journal of Basic and Clinical
Pharmacy 2010, 1, 177-181.
254. http://zipcodezoo.com/Plants/G/Gendarussa_vulgaris/
255. http://www.naturalmedicinalherbs.net/herbs/j/justicia-gendarussa.php
256. http://shodhganga.inflibnet.ac.in/bitstream/10603/349/10/10_chapter4.pdf
257. http://taxonomicon.taxonomy.nl/TaxonName.aspx?id=673328&tree=0.1
258. zipcodezoo.com/Plants/L/Lepidagathis_cuspidata/
259. ayurvedicmedicinalplants.com/index.php?option=com_zoom&Item=26&page=
view&catid=13&key=8
260. www.arkive.org/pentatropis/pentatropis-nivalis/image-G126696.html
261. ayurvedicmedicinalplants.com/index.php?option=com_zoom&Item=26&page=
view&catid=22&key=10
262. ayurvedicmedicinalplants.com/index.php?option=com_zoom&Item=26&page=
view&catid=22&key=0
263. Mosmann, T. Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. Journal of immunological
methods 1983, 65, 55-63. 264. Ahmed, F.; Sayeed, A.; Islam, A.; Salam, S. M. A.; Sadik, G.; Sattar, M. A.;
Khan, G. R. M. A. M. Antimicrobial Activity of Extracts and a Glycoside from
Vanda roxburghii Br. Pakistan Journal of Biological Sciences 2002, 5, 189-191. 265. Rogers, L. L.; Zeng, L.; Kozlowski, J. F.; Shimada, H.; Alali, F. Q.; Johnson, H.
A.; McLaughlin, J. L. New bioactive triterpenoids from Melia volkensii. Journal
of natural products 1998, 61, 64-70. 266. Ahmed, F.; Sayeed, A.; Islam, A.; Salam, S. M. A.; Sadik, G.; Khan, G. R. M.
A. M. Characterization and in vitro Antimicrobial Activity of 17-ßhydroxy-14,
20-epoxy-1-oxo-[22R]-3ß [O-ßd-glucopyranosyl]-5, 24-withadienolide from
Vanda roxburghii Br. Journal of Medical Sciences 2001, 1, 324-326.
References
166
267. Ahmed, F.; Sayeed, A.; Islam, A.; Salam, S. M. A.; Sadik, G.; Sattar, M. A.;
Khan, G. R. M. A. M. Antimicrobial Activity of Extracts and a Glycoside from
Vanda roxburghii Br. Pakistan Journal of Biological Sciences 2002, 5, 189-191.